Salarius Pharmaceuticals Files 8-K Report
Ticker: DCOY · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1615219
Sentiment: neutral
Topics: corporate-event, filing, securities
Related Tickers: SLRX
TL;DR
Salarius Pharma (SLRX) filed an 8-K on 6/14, watch for security holder rights changes.
AI Summary
On June 14, 2024, Salarius Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to security holder rights and other events. The company, formerly known as Flex Pharma, Inc., is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This 8-K filing indicates potential changes affecting Salarius Pharmaceuticals' security holders and other corporate events, requiring investor attention.
Risk Assessment
Risk Level: medium — 8-K filings can signal significant corporate changes, but the specific details of the modifications to security holder rights are not yet fully disclosed in this summary.
Key Numbers
- 001-36812 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5087339 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- Flex Pharma, Inc. (company) — Former Company Name
- June 14, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Houston, TX (location) — Principal Executive Offices
FAQ
What specific material modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders, but the specific details are not provided in the summary text.
What other events are reported in this 8-K filing?
The filing mentions 'Other Events' and 'Financial Statements and Exhibits' in addition to modifications to security holder rights and amendments to articles of incorporation or bylaws.
When was Salarius Pharmaceuticals, Inc. formerly known as Flex Pharma, Inc.?
The date of the name change from Flex Pharma, Inc. to Salarius Pharmaceuticals, Inc. was July 30, 2014.
What is the principal executive office address for Salarius Pharmaceuticals, Inc.?
The principal executive offices are located at 2450 Holcombe Blvd., Suite X, Houston, TX 77021.
What is the fiscal year end for Salarius Pharmaceuticals, Inc.?
The fiscal year end for Salarius Pharmaceuticals, Inc. is December 31st.
Filing Stats: 1,086 words · 4 min read · ~4 pages · Grade level 11.3 · Accepted 2024-06-14 16:04:58
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
Filing Documents
- flks-20240614.htm (8-K) — 35KB
- slrx-certificateofamendm.htm (EX-3.1) — 5KB
- a061224slrxreversesplit-fi.htm (EX-99.1) — 13KB
- image_0a.jpg (GRAPHIC) — 75KB
- slrx-certificateofamendm001.jpg (GRAPHIC) — 268KB
- slrx-certificateofamendm002.jpg (GRAPHIC) — 52KB
- slrx-certificateofamendm003.jpg (GRAPHIC) — 49KB
- 0001615219-24-000045.txt ( ) — 797KB
- flks-20240614.xsd (EX-101.SCH) — 2KB
- flks-20240614_lab.xml (EX-101.LAB) — 22KB
- flks-20240614_pre.xml (EX-101.PRE) — 13KB
- flks-20240614_htm.xml (XML) — 3KB
03 Material Modification to Rights of Security Holders
Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this report is incorporated herein by reference.
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 14, 2024, Salarius Pharmaceuticals, Inc. (the "Company") filed a Certificate of Amendment to the Company's amended and restated certificate of incorporation (the "Certificate of Amendment"), with the Secretary of State of the State of Delaware, to effect a 1-for-8 reverse stock split (the "reverse split") of the Company's issued and outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"), effective at 5:00 p.m. Eastern Time on that date (the "Effective Date"). Beginning with the opening of trading on June 17, 2024, the Company's Common Stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X404. As a result of the reverse split, each eight shares of the Company's Common Stock issued and outstanding will be automatically combined and converted into one issued and outstanding share of Common Stock. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to a fractional share of Common Stock will instead receive cash in lieu of fractional shares based on the closing price per share of the Company's Common Stock as quoted on the Nasdaq Capital Market on the Effective Date (as adjusted to give effect to the reverse split). The reverse split will not reduce the number of authorized shares of Common Stock or preferred stock (the "Preferred Stock"), or change the par values of the Company's Common Stock or Preferred Stock. The reverse split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of the Company's shares of Common Stock (except to the extent that the reverse split would result in some of the stockholders receiving cash in lieu of fractional shares). All outstanding options and warrants entitling their holders to purchase shares of the Company's Common Stock will be adjusted as a result
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the reverse split and the timing thereof. The risks and uncertainties relating to the Company include general market conditions as well as other risks detailed from time to time in the Company's Securities and Exchange Commission filings, including in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events. On June 12, 2024, the Company issued a press release announcing the reverse split. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Salarius Pharmaceuticals, Inc., effective June 14, 2024 99.1 Press Release of Salarius Pharmaceuticals, Inc., dated June 12, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: June 14, 2024 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Chief Financial Officer